Compare GKOS & ALSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GKOS | ALSN |
|---|---|---|
| Founded | 1998 | 1915 |
| Country | United States | United States |
| Employees | N/A | 4000 |
| Industry | Medical/Dental Instruments | Auto Parts:O.E.M. |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.0B | 9.9B |
| IPO Year | 2015 | 2011 |
| Metric | GKOS | ALSN |
|---|---|---|
| Price | $153.58 | $122.34 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 12 | 7 |
| Target Price | ★ $126.92 | $117.57 |
| AVG Volume (30 Days) | 692.4K | ★ 1.4M |
| Earning Date | 04-29-2026 | 05-04-2026 |
| Dividend Yield | N/A | ★ 0.84% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 1.33 |
| Revenue | $507,442,000.00 | ★ $3,010,000,000.00 |
| Revenue This Year | $23.32 | $94.98 |
| Revenue Next Year | $27.43 | $5.30 |
| P/E Ratio | ★ N/A | $89.95 |
| Revenue Growth | ★ 32.33 | N/A |
| 52 Week Low | $73.16 | $76.01 |
| 52 Week High | $161.53 | $137.62 |
| Indicator | GKOS | ALSN |
|---|---|---|
| Relative Strength Index (RSI) | 61.97 | 60.24 |
| Support Level | $96.44 | $112.48 |
| Resistance Level | $161.53 | $127.38 |
| Average True Range (ATR) | 5.46 | 3.11 |
| MACD | -0.85 | 0.81 |
| Stochastic Oscillator | 55.40 | 88.04 |
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Allison Transmission is the largest manufacturer of fully automatic transmissions for medium- and heavy-duty commercial vehicles. Its automatic transmissions allow customers to achieve better fuel and operator efficiency than less expensive manual and automated manual transmissions. Allison serves several end markets, including on- and off-highway equipment and military vehicles. Its on-highway business commands approximately 60% global market share. The company's transmissions can be found in Class 4-8 trucks, buses, and a limited number of large passenger vehicles (heavy-duty pickup trucks and motorhomes). Allison also produces commercial hybrid propulsion systems and is developing fully electric powertrains.